SETD6 regulates NF-κB signaling in urothelial cell survival: Implications for bladder cancer

Neelam Mukherjee, Eduardo Cardenas, Roble Bedolla, Rita Ghosh

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Non-muscle invasive bladder cancer has a high recurrence rate of 45-70%, progressing to muscle invasive disease in about 15% of those patients over a 5-year period. Administration of the mycobacterium, Bacillus Calmette-Guerin (BCG) that induces local inflammation resulting in tumor remission in responsive patients is frequently used for treatment. BCG-treated patients with NF-κB del/del genotype have an increased risk of recurrence suggesting an important role of NF-κB in bladder cancer. Since protein methyltransferases play critical roles in modulating chromatin structure and gene expression, we screened a focused array of epigenetic modification genes to identify differential expression between normal urothelial and bladder cancer cells. We found and validated high expression of the SET-domaincontaining protein methyltransferase, SETD6. SETD6 monomethylates NF-κB-p65 at lysine 310. Our results show that primary urothelial cells and normal bladder tissue have nearly undetectable message and protein level of SETD6 that increases in transformed urothelial cells and is further increased in bladder cancer cells and tissues. Overexpression of SETD6 in transformed urothelial cells increased cell survival and colony formation while knockdown in cancer cells decreased both parameters. Luciferase reporter assays showed that SETD6 induced the canonical NF-κB signaling pathway. Further, the use of catalytic SETD6 and IκBα mutant shows that SETD6 positively regulates survival by affecting p65 message, protein level and its function as determined by increased expression of NF-κB target genes. Our findings suggest that SETD6 plays an important role in NF-κB regulation and may have an important role in NF-κB-mediated local inflammatory response following BCG treatment.

Original languageEnglish (US)
Pages (from-to)15114-15125
Number of pages12
JournalOncotarget
Volume8
Issue number9
DOIs
StatePublished - 2017

Fingerprint

Urinary Bladder Neoplasms
Cell Survival
Mycobacterium bovis
Protein Methyltransferases
Recurrence
Mycobacterium
Luciferases
Epigenomics
Genes
Lysine
Chromatin
Neoplasms
Urinary Bladder
Proteins
Genotype
Inflammation
Gene Expression
Muscles
Survival
Therapeutics

Keywords

  • Bladder cancer
  • Methyltransferase
  • NF-κB
  • SETD6
  • Signaling

ASJC Scopus subject areas

  • Oncology

Cite this

SETD6 regulates NF-κB signaling in urothelial cell survival : Implications for bladder cancer. / Mukherjee, Neelam; Cardenas, Eduardo; Bedolla, Roble; Ghosh, Rita.

In: Oncotarget, Vol. 8, No. 9, 2017, p. 15114-15125.

Research output: Contribution to journalArticle

Mukherjee, Neelam ; Cardenas, Eduardo ; Bedolla, Roble ; Ghosh, Rita. / SETD6 regulates NF-κB signaling in urothelial cell survival : Implications for bladder cancer. In: Oncotarget. 2017 ; Vol. 8, No. 9. pp. 15114-15125.
@article{f580eba39b4e4ca0b7f662a3e593a545,
title = "SETD6 regulates NF-κB signaling in urothelial cell survival: Implications for bladder cancer",
abstract = "Non-muscle invasive bladder cancer has a high recurrence rate of 45-70{\%}, progressing to muscle invasive disease in about 15{\%} of those patients over a 5-year period. Administration of the mycobacterium, Bacillus Calmette-Guerin (BCG) that induces local inflammation resulting in tumor remission in responsive patients is frequently used for treatment. BCG-treated patients with NF-κB del/del genotype have an increased risk of recurrence suggesting an important role of NF-κB in bladder cancer. Since protein methyltransferases play critical roles in modulating chromatin structure and gene expression, we screened a focused array of epigenetic modification genes to identify differential expression between normal urothelial and bladder cancer cells. We found and validated high expression of the SET-domaincontaining protein methyltransferase, SETD6. SETD6 monomethylates NF-κB-p65 at lysine 310. Our results show that primary urothelial cells and normal bladder tissue have nearly undetectable message and protein level of SETD6 that increases in transformed urothelial cells and is further increased in bladder cancer cells and tissues. Overexpression of SETD6 in transformed urothelial cells increased cell survival and colony formation while knockdown in cancer cells decreased both parameters. Luciferase reporter assays showed that SETD6 induced the canonical NF-κB signaling pathway. Further, the use of catalytic SETD6 and IκBα mutant shows that SETD6 positively regulates survival by affecting p65 message, protein level and its function as determined by increased expression of NF-κB target genes. Our findings suggest that SETD6 plays an important role in NF-κB regulation and may have an important role in NF-κB-mediated local inflammatory response following BCG treatment.",
keywords = "Bladder cancer, Methyltransferase, NF-κB, SETD6, Signaling",
author = "Neelam Mukherjee and Eduardo Cardenas and Roble Bedolla and Rita Ghosh",
year = "2017",
doi = "10.18632/oncotarget.14750",
language = "English (US)",
volume = "8",
pages = "15114--15125",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "9",

}

TY - JOUR

T1 - SETD6 regulates NF-κB signaling in urothelial cell survival

T2 - Implications for bladder cancer

AU - Mukherjee, Neelam

AU - Cardenas, Eduardo

AU - Bedolla, Roble

AU - Ghosh, Rita

PY - 2017

Y1 - 2017

N2 - Non-muscle invasive bladder cancer has a high recurrence rate of 45-70%, progressing to muscle invasive disease in about 15% of those patients over a 5-year period. Administration of the mycobacterium, Bacillus Calmette-Guerin (BCG) that induces local inflammation resulting in tumor remission in responsive patients is frequently used for treatment. BCG-treated patients with NF-κB del/del genotype have an increased risk of recurrence suggesting an important role of NF-κB in bladder cancer. Since protein methyltransferases play critical roles in modulating chromatin structure and gene expression, we screened a focused array of epigenetic modification genes to identify differential expression between normal urothelial and bladder cancer cells. We found and validated high expression of the SET-domaincontaining protein methyltransferase, SETD6. SETD6 monomethylates NF-κB-p65 at lysine 310. Our results show that primary urothelial cells and normal bladder tissue have nearly undetectable message and protein level of SETD6 that increases in transformed urothelial cells and is further increased in bladder cancer cells and tissues. Overexpression of SETD6 in transformed urothelial cells increased cell survival and colony formation while knockdown in cancer cells decreased both parameters. Luciferase reporter assays showed that SETD6 induced the canonical NF-κB signaling pathway. Further, the use of catalytic SETD6 and IκBα mutant shows that SETD6 positively regulates survival by affecting p65 message, protein level and its function as determined by increased expression of NF-κB target genes. Our findings suggest that SETD6 plays an important role in NF-κB regulation and may have an important role in NF-κB-mediated local inflammatory response following BCG treatment.

AB - Non-muscle invasive bladder cancer has a high recurrence rate of 45-70%, progressing to muscle invasive disease in about 15% of those patients over a 5-year period. Administration of the mycobacterium, Bacillus Calmette-Guerin (BCG) that induces local inflammation resulting in tumor remission in responsive patients is frequently used for treatment. BCG-treated patients with NF-κB del/del genotype have an increased risk of recurrence suggesting an important role of NF-κB in bladder cancer. Since protein methyltransferases play critical roles in modulating chromatin structure and gene expression, we screened a focused array of epigenetic modification genes to identify differential expression between normal urothelial and bladder cancer cells. We found and validated high expression of the SET-domaincontaining protein methyltransferase, SETD6. SETD6 monomethylates NF-κB-p65 at lysine 310. Our results show that primary urothelial cells and normal bladder tissue have nearly undetectable message and protein level of SETD6 that increases in transformed urothelial cells and is further increased in bladder cancer cells and tissues. Overexpression of SETD6 in transformed urothelial cells increased cell survival and colony formation while knockdown in cancer cells decreased both parameters. Luciferase reporter assays showed that SETD6 induced the canonical NF-κB signaling pathway. Further, the use of catalytic SETD6 and IκBα mutant shows that SETD6 positively regulates survival by affecting p65 message, protein level and its function as determined by increased expression of NF-κB target genes. Our findings suggest that SETD6 plays an important role in NF-κB regulation and may have an important role in NF-κB-mediated local inflammatory response following BCG treatment.

KW - Bladder cancer

KW - Methyltransferase

KW - NF-κB

KW - SETD6

KW - Signaling

UR - http://www.scopus.com/inward/record.url?scp=85014075229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014075229&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.14750

DO - 10.18632/oncotarget.14750

M3 - Article

AN - SCOPUS:85014075229

VL - 8

SP - 15114

EP - 15125

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 9

ER -